Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”

A recent study by Zimmerman et al. (2023) reported non-significant higher relative vaccine effectiveness of recombinant (RIV4) over the standard-dose influenza vaccines (SDIV) against outpatient illness during the 2018–19 and 2019–20 vaccination seasons. We agree with the authors’ conclusions and wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadigal, Sanjay, Colombo, Laura, Haughie, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Influenza
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288927/
https://www.ncbi.nlm.nih.gov/pubmed/37344371
http://dx.doi.org/10.1080/21645515.2023.2227034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288927/
https://www.ncbi.nlm.nih.gov/pubmed/37344371
http://dx.doi.org/10.1080/21645515.2023.2227034

Ejemplares similares